152 related articles for article (PubMed ID: 23102054)
1. Synthesis and evaluation of the aldolase antibody-derived chemical-antibodies targeting α5β1 integrin.
Goswami RK; Liu Y; Liu C; Lerner RA; Sinha SC
Mol Pharm; 2013 Feb; 10(2):538-43. PubMed ID: 23102054
[TBL] [Abstract][Full Text] [Related]
2. Multiple catalytic aldolase antibodies suitable for chemical programming.
Goswami RK; Huang ZZ; Forsyth JS; Felding-Habermann B; Sinha SC
Bioorg Med Chem Lett; 2009 Jul; 19(14):3821-4. PubMed ID: 19428247
[TBL] [Abstract][Full Text] [Related]
3. Preparation of integrin alpha(v)beta3-targeting Ab 38C2 constructs.
Sinha SC; Das S; Li LS; Lerner RA; Barbas CF
Nat Protoc; 2007; 2(2):449-56. PubMed ID: 17406606
[TBL] [Abstract][Full Text] [Related]
4. Chemically Programmed Bispecific Antibody Targeting Legumain Protease and αvβ3 Integrin Mediates Strong Antitumor Effects.
Liu Y; Goswami RK; Liu C; Sinha SC
Mol Pharm; 2015 Jul; 12(7):2544-50. PubMed ID: 26024761
[TBL] [Abstract][Full Text] [Related]
5. Small molecule drug activity in melanoma models may be dramatically enhanced with an antibody effector.
Popkov M; Rader C; Gonzalez B; Sinha SC; Barbas CF
Int J Cancer; 2006 Sep; 119(5):1194-207. PubMed ID: 16570283
[TBL] [Abstract][Full Text] [Related]
6. A humanized aldolase antibody for selective chemotherapy and adaptor immunotherapy.
Rader C; Turner JM; Heine A; Shabat D; Sinha SC; Wilson IA; Lerner RA; Barbas CF
J Mol Biol; 2003 Sep; 332(4):889-99. PubMed ID: 12972259
[TBL] [Abstract][Full Text] [Related]
7. Beta-lactam-based approach for the chemical programming of aldolase antibody 38C2.
Gavrilyuk JI; Wuellner U; Barbas CF
Bioorg Med Chem Lett; 2009 Mar; 19(5):1421-4. PubMed ID: 19181522
[TBL] [Abstract][Full Text] [Related]
8. Enhancing the synthetic utility of aldolase antibody 38C2.
Mondal K; Ramesh NG; Roy I; Gupta MN
Bioorg Med Chem Lett; 2006 Feb; 16(4):807-10. PubMed ID: 16321532
[TBL] [Abstract][Full Text] [Related]
9. A cofactor approach to copper-dependent catalytic antibodies.
Nicholas KM; Wentworth P; Harwig CW; Wentworth AD; Shafton A; Janda KD
Proc Natl Acad Sci U S A; 2002 Mar; 99(5):2648-53. PubMed ID: 11880619
[TBL] [Abstract][Full Text] [Related]
10. Enantioselective aldol cyclodehydrations catalyzed by antibody 38C2.
List B; Lerner RA; Barbas CF
Org Lett; 1999 Jul; 1(1):59-61. PubMed ID: 10822533
[TBL] [Abstract][Full Text] [Related]
11. A function blocking anti-mouse integrin alpha5beta1 antibody inhibits angiogenesis and impedes tumor growth in vivo.
Bhaskar V; Zhang D; Fox M; Seto P; Wong MH; Wales PE; Powers D; Chao DT; Dubridge RB; Ramakrishnan V
J Transl Med; 2007 Nov; 5():61. PubMed ID: 18042290
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of the next-generation therapeutic antibodies that combine cell targeting and antibody-catalyzed prodrug activation.
Abraham S; Guo F; Li LS; Rader C; Liu C; Barbas CF; Lerner RA; Sinha SC
Proc Natl Acad Sci U S A; 2007 Mar; 104(13):5584-9. PubMed ID: 17372220
[TBL] [Abstract][Full Text] [Related]
13. alpha5beta1 integrin antagonists reduce chemotherapy-induced premature senescence and facilitate apoptosis in human glioblastoma cells.
Martinkova E; Maglott A; Leger DY; Bonnet D; Stiborova M; Takeda K; Martin S; Dontenwill M
Int J Cancer; 2010 Sep; 127(5):1240-8. PubMed ID: 20099278
[TBL] [Abstract][Full Text] [Related]
14. Evolution of aldolase antibodies in vitro: correlation of catalytic activity and reaction-based selection.
Tanaka F; Fuller R; Shim H; Lerner RA; Barbas CF
J Mol Biol; 2004 Jan; 335(4):1007-18. PubMed ID: 14698295
[TBL] [Abstract][Full Text] [Related]
15. Computational elucidation and validation of the three-dimensional structure of humanized aldolase catalytic antibody 38C2.
Jayakody RS; Jasin Arachchige LI; Japahuge A
J Biomol Struct Dyn; 2021 Apr; 39(7):2463-2477. PubMed ID: 32242499
[TBL] [Abstract][Full Text] [Related]
16. Single cell tracking assay reveals an opposite effect of selective small non-peptidic α5β1 or αvβ3/β5 integrin antagonists in U87MG glioma cells.
Ray AM; Schaffner F; Janouskova H; Noulet F; Rognan D; Lelong-Rebel I; Choulier L; Blandin AF; Lehmann M; Martin S; Kapp T; Neubauer S; Rechenmacher F; Kessler H; Dontenwill M
Biochim Biophys Acta; 2014 Sep; 1840(9):2978-87. PubMed ID: 24810979
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of adhesion, migration and of α5β1 integrin in the HCT-116 colorectal cancer cells treated with the ruthenium drug NAMI-A.
Pelillo C; Mollica H; Eble JA; Grosche J; Herzog L; Codan B; Sava G; Bergamo A
J Inorg Biochem; 2016 Jul; 160():225-35. PubMed ID: 26961176
[TBL] [Abstract][Full Text] [Related]
18. Antibody-catalyzed benzoin oxidation as a mechanistic probe for nucleophilic catalysis by an active site lysine.
Sklute G; Oizerowich R; Shulman H; Keinan E
Chemistry; 2004 May; 10(9):2159-65. PubMed ID: 15112204
[TBL] [Abstract][Full Text] [Related]
19. In vivo analysis of Arg-Gly-Asp sequence/integrin α5β1-mediated signal involvement in embryonic enchondral ossification by exo utero development system.
Inoue T; Hashimoto R; Matsumoto A; Jahan E; Rafiq AM; Udagawa J; Hatta T; Otani H
J Bone Miner Res; 2014 Jul; 29(7):1554-63. PubMed ID: 24375788
[TBL] [Abstract][Full Text] [Related]
20. The small alpha5beta1 integrin antagonist, SJ749, reduces proliferation and clonogenicity of human astrocytoma cells.
Maglott A; Bartik P; Cosgun S; Klotz P; Rondé P; Fuhrmann G; Takeda K; Martin S; Dontenwill M
Cancer Res; 2006 Jun; 66(12):6002-7. PubMed ID: 16778170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
